Facebook
Twitter
LinkedIn
Forward
CRPC: Education to Improve Services to Patients with OUD/SUD
These activities are part of the education provided for the California Residency Program Collaborative (CRPC) and available to the general public to improve education, outreach, and treatment for patients with Substance Use Disorder (SUD), including stimulant use disorder, and opioid use disorder with a focus on increasing capacity for effective Medication Assisted Treatment (MAT) implementation. Most of the activities are accredited for CME. For more information, go to www.familydocs.org/crpc.
Activities:
- Screening and Identifying Opioid Use and Substance Use Disorder
- Medication Assisted Treatment (MAT) and its Utility to Treating OUD
- Pregnancy and Women's SUD
- Communication Matters: Motivational Interviewing and Substance Use Disorders
- Medication Assisted Treatments (MAT) for Opiates, But What About Stimulants?
- Telehealth for Substance Use
- Is Addiction a Brain Disease?
- The Role of Abstinence in OUD Treatment
- Opioid and Substance Use Disorders in Special Populations: Youth and Young Adult Athletes
- Treating SUD - Linking with Community Services
- Incorporating MAT into Practice - A Community Conversation
- Quick Start to Prescribing Buprenorphine and CA Bridge Resource Overview
- Stigma, Substance Use and the House of Medicine
- Getting Started in Quality Improvement
- Quality Improvement Basics Starting with Goals and Specific Aims
Support:
This activity is supported by the California Academy of Family Physicians Foundation with a grant from the California Department of Healthcare Services.
Target Audience:
This activity is intended for family medicine physicians, and other primary care providers and clinicians caring for patients with substance use disorder disease.
Thomas Bent, MD, Family Physician, Laguna Beach Community Clinic
Carol Havens, MD, Family Physician and Addiction Medicine Specialist
Tipu Khan, MD, FAAFP, FASAM, Program Director, Ventura County Medical Center Primary Care Addiction Medicine Fellowship
Benjamin Leong, MD, MPH, Family Physician, Kaiser Permanente
Karen Muchowski, MD, FAAFP, Family Physician, Greybill Medical Group
Lauren M. Simon, MD, MPH, FAAFP, FAMSSM, Professor of Family Medicine, Loma Linda University
Hannah Snyder, MD, C-Principal Investigator, CA Bridge; Clinical Assistant Professor in the Department of Family and Community Medicine at the UC San Francisco
Allen Wang, MD, MPH, Emergency Medicine Physician, Kaiser Permanente
Conflict of Interest Statements:
The Committee on Continuing Professional Development and CME will be responsible for mitigating any relevant financial relationships disclosed by an individual who may have influence on content, who have served as faculty, or who may produce CME/CPD content for the CAFP. Mitigation may include learner notification, peer review of content before presentation, requirement of EB-CME, changing topics, or even dismissing a potential faculty member.
It is the policy of the CAFP to ensure independence, balance, objectivity, scientific rigor, and integrity in all continuing education activities. All individuals with potential to influence the content of this program have submitted Disclosure of Interest declarations that have been reviewed according to policy. Learner notification of declarations is below. All individuals with relevant financial relationships with ineligible companies have been contacted by CAFP staff or CCPD members, and issues of conflict have been discussed and mitigated.
Faculty Disclosure:
Tipu Khan is a consultant and speaker for AbbVie pharmaceutical company, a consultant for Indivior pharmaceutical company, and was formerly a speaker for Alkermes pharmaceutical company, all on the topic of Hepatitis C. These relevant financial relationships have been mitigated.
Karen Muchowski is an investor in Defined Research, a company addressing insomnia through use of CBD. This relevant financial relationship has been mitigated.
Allen Wang is a retail investor in two early-stage biopharmaceutical companies, Atossa Genetics and Tonix Therapeutics, unrelated to substance use disorders. These relevant financial relationships have been mitigated.
All other faculty declare that they have no financial relationships with ineligible companies to disclose.
CME Planners:
The following planners have no financial relationships with ineligible companies to disclose: Shelly B. Rodrigues, MS, CAE, FACEHP, FAAMSE, Jerri L. Davis, CHCP
The AAFP has reviewed CRPC: Education to Improve Services to Patients with OUD/SUD, and deemed it acceptable for AAFP credit. Term of approval is from 08/23/2022 to 08/23/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit approval includes the following session(s):
- 0.50 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Identifying/Screening for Opioid Use and Substance Use Disorder
- 0.75 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Medication Assisted Treatment (MAT) and its Utility to Treating OUD
- 0.75 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Pregnancy and Women's SUD
- 0.75 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Communication Matters: Motivational Interviewing and Substance Use Disorders
- 1.00 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Medication Assisted Treatments (MAT) for Opiates, But What About Stimulants?
- 0.50 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Telehealth for Substance Use
- 0.50 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Is Addiction a Brain Disease?
- 0.50 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - The Role of Abstinence in OUD Treatment
- 1.25 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Opioid and Substance Use Disorders in Special Populations
- 1.00 Enduring Materials, Self-Study AAFP Prescribed Credit(s) - Stigma, Substance Use and the House of Medicine